Fulcrum stockholders elect three Class I directors, approve advisory compensation, ratify auditor

Fulcrum Therapeutics, Inc.

Sonja Banks, Alan Ezekowitz, Colin Hill elected as Class I directors for three-year terms ending 2029.
Advisory vote on named executive officer compensation approved with 50.7M for, 3.0M against.
Ratification of Ernst & Young as FY2026 auditor approved with 58.8M for, 36K against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.